These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9842095)

  • 21. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream.
    Schaen L; Mercurio MG
    Pediatr Dermatol; 2001; 18(5):450-2. PubMed ID: 11737697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imiquimod.
    Garland SM
    Curr Opin Infect Dis; 2003 Apr; 16(2):85-9. PubMed ID: 12734440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Imiquimod--clinical efficacy].
    Beutner KR
    Ann Dermatol Venereol; 2000; 127(10 Suppl):3S19-3S21. PubMed ID: 11116859
    [No Abstract]   [Full Text] [Related]  

  • 24. Imiquimod applied topically: A novel immune response modifier.
    Tyring S
    Skin Therapy Lett; 2001 Mar; 6(6):1-4. PubMed ID: 11298484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of imiquimod in anogenital warts from HIV-positive men.
    Herrera S; Correa LA; Wolff JC; Gaviria A; Tyring SK; Sanclemente G
    J Clin Virol; 2007 Jul; 39(3):210-4. PubMed ID: 17513167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions.
    Carrasco D; vander Straten M; Tyring SK
    J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S212-6. PubMed ID: 12271280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.
    Fife KH; Ferenczy A; Douglas JM; Brown DR; Smith M; Owens ML;
    Sex Transm Dis; 2001 Apr; 28(4):226-31. PubMed ID: 11318254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using imiquimod for genital warts in female patients.
    Cox JT; Petry KU; Rylander E; Roy M
    J Womens Health (Larchmt); 2004 Apr; 13(3):265-71. PubMed ID: 15130255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatments for genital warts less than ideal: abstract and commentary.
    Fife KH
    JAMA; 1998 Jun; 279(24):2003-4. PubMed ID: 9643868
    [No Abstract]   [Full Text] [Related]  

  • 30. Imiquimod in clinical practice.
    Edwards L
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S12-7. PubMed ID: 10861102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of perianal warts in a child with 5% imiquimod cream.
    Gruber PC; Wilkinson J
    J Dermatolog Treat; 2001 Dec; 12(4):215-7. PubMed ID: 12241631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imiquimod as an immune response modulator in infectious conditions.
    Skinner RB
    Postgrad Med; 2002 Dec; 112(6 Suppl Using):8-16. PubMed ID: 19667608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imiquimod for the treatment of genital warts: a quantitative systematic review.
    Moore RA; Edwards JE; Hopwood J; Hicks D
    BMC Infect Dis; 2001; 1():3. PubMed ID: 11401728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic approaches to genital warts.
    Beutner KR; Ferenczy A
    Am J Med; 1997 May; 102(5A):28-37. PubMed ID: 9217660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of imiquimod 3.75% cream in the treatment of external genital warts.
    Berman B; Wolf J
    Skin Therapy Lett; 2012 Apr; 17(4):5-7. PubMed ID: 22491804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies.
    Schöfer H
    Br J Dermatol; 2007 Dec; 157 Suppl 2():52-5. PubMed ID: 18067633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory and pharmacologic properties of imiquimod.
    Sauder DN
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the applications of imiquimod: a novel immune response modifier.
    Syed TA
    Expert Opin Pharmacother; 2001 May; 2(5):877-82. PubMed ID: 12219723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
    Imbertson LM; Beaurline JM; Couture AM; Gibson SJ; Smith RM; Miller RL; Reiter MJ; Wagner TL; Tomai MA
    J Invest Dermatol; 1998 May; 110(5):734-9. PubMed ID: 9579537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of topical 5% imiquimod during pregnancy: a case series.
    Einarson A; Costei A; Kalra S; Rouleau M; Koren G
    Reprod Toxicol; 2006 Jan; 21(1):1-2. PubMed ID: 16039826
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.